Ipamorelin GH Safety: Selectivity, Dosing & Comparison to GHRP-2 and GHRP-6

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a) — the ghrelin receptor. It was developed in the 1990s at Novo Nordisk and studied in Phase I and Phase II clinical trials for postoperative ileus before development was discontinued. Its pharmacological profile — selective GH release without meaningful cortisol or prolactin elevation — distinguishes it from older GHRPs and drives its continued research interest.

Selective GH Secretagogue: What Selectivity Means

GH secretagogues stimulate pituitary GH release through GHSR-1a. The critical pharmacological question is whether receptor activation at this receptor also triggers the release of other pituitary hormones, particularly cortisol (via ACTH) and prolactin. GHRP-2 and GHRP-6, the older GHRPs, stimulate GH robustly but also significantly elevate cortisol and, to a lesser extent, prolactin at therapeutic doses. Ipamorelin was engineered to be selective: at doses that produce substantial GH pulses, ipamorelin causes minimal ACTH/cortisol or prolactin elevation. This was demonstrated in preclinical studies by Raun et al. (1998) in the European Journal of Endocrinology.

Comparison to GHRP-2 and GHRP-6

GHRP-2 (pralmorelin) is the most potent GHRP for GH release but produces the most pronounced ACTH/cortisol elevation. GHRP-6 causes significant hunger as a side effect (the ghrelin receptor in the hypothalamus also regulates appetite) and moderate cortisol elevation. Ipamorelin produces GH pulses of comparable magnitude to GHRP-2 at equivalent doses in some models, with the key differentiation being the cortisol/prolactin selectivity. For researchers concerned about the chronic cortisol elevation associated with older GHRPs, ipamorelin is the preferred alternative.

Hunger stimulation (a GHRP-6 problem via hypothalamic ghrelin signaling) is also significantly attenuated with ipamorelin — this is practically important for researchers who find appetite stimulation a limiting side effect.

Typical Research Doses

In clinical trials for postoperative ileus, ipamorelin was administered at doses from 10 to 400 μg/kg IV. Community research protocols for GH-axis modulation typically use 100–300 μg per injection subcutaneously, administered 1–3 times daily. The rationale for multiple daily injections is that GH secretion is pulsatile: ipamorelin mimics a GH pulse, and administering it at consistent intervals (e.g., morning, pre-workout, pre-sleep) is intended to preserve or amplify the physiological pulsatile pattern rather than creating sustained GH elevation.

Pulse vs. Continuous Dosing

GH acts on the liver to stimulate IGF-1 production, and the pattern of GH secretion (pulsatile vs. continuous) significantly affects IGF-1 output and anabolic signaling. Pulsatile GH exposure (as occurs naturally) produces higher peak IGF-1 levels and more anabolic signaling per unit of total GH secreted compared to continuous infusion. Ipamorelin, when dosed at discrete intervals (2–3 times per day), preserves the pulsatile pattern better than continuous GH administration. This is the primary rationale for multi-injection protocols over a single large daily dose.

Safety Profile and Known Risks

In its clinical trial program (Phase I and Phase II), ipamorelin’s adverse event profile was generally mild. The most commonly noted effects are water retention (from increased IGF-1 and GH action on sodium retention), flushing, and headache. Unlike continuous recombinant GH administration, ipamorelin and other GHRPs do not bypass the GH/IGF-1 axis’s feedback mechanisms entirely — somatostatin feedback limits the GH pulses elicited. This may reduce the risk of the acromegaly-like effects (carpal tunnel, joint swelling, glucose intolerance) associated with supraphysiologic GH administration.

Long-term safety data for ipamorelin in human subjects is limited — the clinical trial program was not completed. Researchers should note that any chronic stimulation of the GH/IGF-1 axis carries theoretical risks related to oncogenesis, given IGF-1’s role as a growth factor. No clinical data has established this risk from GHRP-class peptides specifically, but the theoretical concern should be factored into protocol duration decisions.

Combination with CJC-1295

Ipamorelin is frequently combined with CJC-1295 (a GHRH analog) in community research protocols. The rationale is synergistic: CJC-1295 acts on a different receptor (GHRH receptor) to prime the pituitary for GH release, while ipamorelin triggers the actual GH pulse via GHSR-1a. The combination is sometimes formulated as a blend (ipamorelin/CJC-1295). See the Pepticker catalog for vendor pricing and purity data on this combination.